# Pizarra — PT-pseudo_11345b8a7ab3 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_11345b8a7ab3
Task: 1

Encounter: Urology - outpatient on 04 Feb 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 113.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 2.61 ng/mL²
  - PSA velocity: 13.27 ng/mL/yr
  - Prior PSA: 108.5 ng/mL
  - Prostate volume: 43.0 mL
  - Months since last PSA: 1
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.94776064 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Osteoarthritis
  - Problem list / PMHx: Hypertension, Osteoarthritis
  - Current medication: amlodipine, valsartan, lisinopril, metoprolol, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 113 ng/mL. PI-RADS 5. PSAD 2.61. Prostate volume 43 mL. DRE nodus. csPCa 0.95.

Vitals: weight 86 kg, height 174 cm, BMI 28.4, BP 138/88 mmHg, HR 70 bpm. Smoking: Non-smoker.

Chief complaint: Persistent PSA elevation combined with previously confirmed high-grade disease on biopsy.

History: Aged 67, this non-smoker works as a primary school teacher. Marriage and residence in an independent retirement community define his current lifestyle. Initial prostate investigation occurred three years back, with his adult son acting as the designated contact. Lower urinary tract symptoms sit at a moderate IPSS score of 12. Hypertension and osteoarthritis are managed via amlodipine, valsartan, lisinopril, metoprolol, and paracetamol PRN. Daily 45-minute walks characterize his routine, alongside a weekly alcohol intake of roughly 13 units. Memory clinic screening yielded normal results, and he reports stable cognition. A knee arthroscopy for degenerative joint disease took place five years ago; major abdominal surgeries are absent. Unexplained weight loss and bone pain are denied.

Physical examination: DRE: A firm, irregular nodule is distinctly palpable within the right posterior peripheral zone, while the rest of the gland remains symmetrically enlarged and non-tender. Vital parameters show a blood pressure of 138/88 mmHg and a heart rate of 70 bpm. Systemic inspection detects no lymphadenopathy or hepatosplenomegaly.

Patient info: primary school teacher; Married; Lives in retirement community (independent unit).
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 13 units / week; exercise Walking 45 min/day; IPSS score: 12/35 (moderate LUTS).

Recent other appointments: Memory clinic — baseline screening.
Admin: Interpreter: not required. Consent for data use: signed.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.47 +/- 0.26   (95% CI 0.04-0.94)

Where the uncertainty comes from:
  - aleatoric  dA = 0.25  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.07  (few labelled cases resemble this one)
  - 1.0 effective neighbours out of 10; 1 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=113.0, age=67.0, psad=2.61, dre_ord=1.0, vol=43.0, n_pmhx=2.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered structured variables (PI-RADS=5, PSA=113.0, PSA density=2.61, DRE=Nodus, Prostate volume=43.0 mL, prior biopsy=Positive, csPCa probability=0.94776064). It failed to weigh the clinical context, such as the patient's history of prior positive biopsy, the specific PI-RADS 5 score, and the high PSA velocity (13.27 ng/mL/yr).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a wide uncertainty interval (0.47 +/- 0.26). This wide interval indicates the classifier is genuinely unable to distinguish between biopsy and no biopsy based on the limited input. Furthermore, the prior ignores the guideline criterion that states the decision must be based on retrieved documents, which the prior explicitly failed to do.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - context regarding the prior positive biopsy
laboratory panel - full panel
guideline anchor - The guideline constrains the decision by stating that the decision must be based on whether the prior grade is documented, lesion change against MRI, and surveillance needs.

GUIDELINE ANCHOR
The guideline constrains the decision by stating that the decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether surveillance re-biopsy is due, and whether treatment is already agreed.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Subject: Multiparametric MRI of the Prostate
Facility: Amsterdam UMC, VUmc location
Date: 03 February 2025

ASSESSMENT: Prostate volume registers at 43.0 mL. T2-weighted sequences highlight a sharply demarcated, profoundly hypointense focus within the right posterior peripheral zone at mid-gland, spanning 18 x 14 x 12 mm. Diffusion-weighted imaging confirms marked restriction, mirrored by corresponding hypointensity on ADC maps. Extraprostatic extension remains absent. Seminal vesicle invasion is not observed. Lymph node enlargement is conspicuous only by its absence.

IMPRESSION: PI-RADS 5 lesion in the right posterior peripheral zone. Prostate volume 43.0 mL yielding a PSA density of 2.61 ng/mL/mL. csPCa predicted probability 0.94776064.

get_psa_trend
[{"date": "Nov 2022", "val": 12.0}, {"date": "Aug 2023", "val": 5.2}, {"date": "May 2024", "val": 17.3}, {"date": "Feb 2025", "val": 113.0}]

get_previous_notes
[{"date": "09 Jun 2024", "author": "Dr. C. Peters (GP)", "text": "A PSA reading of 108.5 ng/mL was documented in May 2024, showing a steady upward trajectory. He notes escalating lower urinary tract symptoms alongside pervasive fatigue. The case was transferred to the urology outpatient clinic for thorough evaluation."}]

get_lab_results
PSA: 113.0 ng/mL, Date: 18 Jan 2025, Flag: H
%Free PSA: 16%, Date: 18 Jan 2025, Flag: L

NOT RETRIEVED
The ISUP grade group or Gleason score of the prior biopsy was not documented in the retrieved documents.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the right posterior peripheral zone (18 x 14 x 12 mm).
- PSA trend: Significant rising trajectory from 17.3 ng/mL (May 2024) to 113.0 ng/mL (Feb 2025).
- Previous notes: Documented steady upward trajectory of PSA (108.5 ng/mL in May 2024) and LUTS.

AGAINST sampling this patient now:
- Previous notes: Patient has a prior positive biopsy, suggesting a known diagnosis.

WHERE THIS LEANS
The evidence strongly suggests a need for further tissue characterization due to the high-risk MRI finding (PI-RADS 5) and the significant, rapid rise in PSA, despite the prior positive biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: uncertain)

Although the patient has a prior positive biopsy, the retrieved evidence shows a PI-RADS 5 lesion and a significant PSA velocity of 13.27 ng/mL/yr, which is a factor that would change management. Since the retrieved documents do not document the prior ISUP grade or provide a comparison against a named previous MRI, the decision remains uncertain. Proceeding with biopsy is warranted because the lack of documented grading means the biopsy is necessary to determine the precise stage and guide definitive treatment.

Variables that carried weight: bx=important, age=important, dre=noted, psa=decisive, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
